BioSpace News Archive

New clinical data highlight potential of novel pyrrolobenzodiazepine-based antibody drug conjugates for the treatment of relapsed or refractory lymphomas

In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week.

The report, which was issued by the Council of Economic Advisors, pointed to changes in the approval process at the FDA in the approval process of generic drugs has led to greater competition in the marketplace, which has lowered the costs of the medications.

‘Hemophilia: The Musical’ allows teens to share their experiences with the genetic disease.

Since taking over as chief executive officer of Swiss pharma giant Novartis, Vas Narasimhan has been actively reshaping the company to focus on therapies that will drive revenue well into the future.

Biomimicry, looking at how things are done in nature and applying that to solve problems, is utilized by many researchers. BioSpace looks at some examples of how scientists are performing cutting-edge research using biomimicry.

The company and the agency discussed the development of SYN-004 (ribaxamase) to prevent antibiotic-mediated Clostridium difficile infection (CDI).

SurGenTec announced today that successful completion of the initial clinical launch of its new GraftGun bone graft delivery system combined with ViBone Viable Bone Matrix prefilled tubes.

Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that preclinical data from SEL120, a CDK8 inhibitor in development for the treatment of acute myeloid leukemia, has been accepted for presentations at the 60th American Society of Hematology (ASH) Annual Meeting taking place Dec. 1-4, 2018, in San Diego.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) previously announced that the Record Date for its 20:1 common stock dividend is November 20, 2018 and that the Payment Date is November 30, 2018 (with an Ex-Date of December 3, 2018).